Here's something you might be interested in.
Ask a Hipster — Advice you didn't know you needed
Big Screen — Movie commentary
Blurt — Music's inside track
Booze News — San Diego spirits
Classical Music — Immortal beauty
Classifieds — Free and easy
Cover Stories — Front-page features
Drinks All Around — Bartenders' drink recipes
Excerpts — Literary and spiritual excerpts
Feast! — Food & drink reviews
Feature Stories — Local news & stories
Fishing Report — What’s getting hooked from ship and shore
From the Archives — Spotlight on the past
Golden Dreams — Talk of the town
The Gonzo Report — Making the musical scene, or at least reporting from it
Letters — Our inbox
Movies@Home — Local movie buffs share favorites
Movie Reviews — Our critics' picks and pans
Musician Interviews — Up close with local artists
Neighborhood News from Stringers — Hyperlocal news
News Ticker — News & politics
Obermeyer — San Diego politics illustrated
Outdoors — Weekly changes in flora and fauna
Overheard in San Diego — Eavesdropping illustrated
Poetry — The old and the new
Reader Travel — Travel section built by travelers
Reading — The hunt for intellectuals
Roam-O-Rama — SoCal's best hiking/biking trails
San Diego Beer — Inside San Diego suds
SD on the QT — Almost factual news
Sheep and Goats — Places of worship
Special Issues — The best of
Street Style — San Diego streets have style
Surf Diego — Real stories from those braving the waves
Theater — On stage in San Diego this week
Tin Fork — Silver spoon alternative
Under the Radar — Matt Potter's undercover work
Unforgettable — Long-ago San Diego
Unreal Estate — San Diego's priciest pads
Your Week — Daily event picks
UCSD's medical school works on female Viagra
Flibanserin affects the central nervous system in as yet unknown ways
San Diego — A drug that bombed as an antidepressant is now being touted by its maker as a possible "female Viagra," and local women wanting to take a chance on the experimental substance in exchange for a new sex life can sign up for trials conducted by UCSD's medical school. "Women who have sexual dysfunction should realize this may be a treatable condition, not just a personal problem," says Thuy-Tien L. Dam, M.D., in a news release put out by the school last month to drum up participants. "Candidates for the study are women who have desire problems; women who once had a healthy sex-drive who now notice a big difference in desire level, for some unknown reason."
Though the release doesn't mention it, the drug in question is known as Flibanserin, developed during the 1990s by German drugmaker Boehringer Ingelheim, which hoped to market it as a treatment for depression. But though experiments showed that the drug reduced stress in laboratory rats, its main effect on humans seemed to be to raise arousal rates in women. So the drug company is now spending millions of dollars on a nationwide experiment with 1400 women in 75 locations, including UCSD, hoping to hit the jackpot if the federal government gives its stamp of approval. But that may not be so easy. Since Flibanserin affects the central nervous system in as yet unknown ways, the Food and Drug Administration is said to be questioning its possible approval as a so-called lifestyle drug marketed solely to enhance sexual activity. Emphasizing possible risks, trial guidelines ban recruiting experimental subjects who have "a history of Major Depressive Disorder within 6 months prior to the start of the study, current suicidal thoughts, or any history of a suicide attempt."
Here's something you might be interested in.
UCSD's medical school works on female Viagra
Flibanserin affects the central nervous system in as yet unknown ways
UCSD's medical school works on female Viagra
Flibanserin affects the central nervous system in as yet unknown ways
San Diego — A drug that bombed as an antidepressant is now being touted by its maker as a possible "female Viagra," and local women wanting to take a chance on the experimental substance in exchange for a new sex life can sign up for trials conducted by UCSD's medical school. "Women who have sexual dysfunction should realize this may be a treatable condition, not just a personal problem," says Thuy-Tien L. Dam, M.D., in a news release put out by the school last month to drum up participants. "Candidates for the study are women who have desire problems; women who once had a healthy sex-drive who now notice a big difference in desire level, for some unknown reason."
Though the release doesn't mention it, the drug in question is known as Flibanserin, developed during the 1990s by German drugmaker Boehringer Ingelheim, which hoped to market it as a treatment for depression. But though experiments showed that the drug reduced stress in laboratory rats, its main effect on humans seemed to be to raise arousal rates in women. So the drug company is now spending millions of dollars on a nationwide experiment with 1400 women in 75 locations, including UCSD, hoping to hit the jackpot if the federal government gives its stamp of approval. But that may not be so easy. Since Flibanserin affects the central nervous system in as yet unknown ways, the Food and Drug Administration is said to be questioning its possible approval as a so-called lifestyle drug marketed solely to enhance sexual activity. Emphasizing possible risks, trial guidelines ban recruiting experimental subjects who have "a history of Major Depressive Disorder within 6 months prior to the start of the study, current suicidal thoughts, or any history of a suicide attempt."
Comments